Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158183 · ClinicalTrials.gov registry record
Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 226
- Enrollment target
NCT01158183: Completed study, sponsored by Bayer.
NCT01158183 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 226 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158183 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 226 participants
- Enrollment target
Study Summary
A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.
Interventions
- DRUG BAY86-5046_Interferon-beta-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-09 |
What the finished NCT01158183 record still lists
NCT01158183 is an observational study that tracks outcomes without assigning an intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BAY86-5046_Interferon-beta-1b is the first listed.
NCT01158183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01158183 about?
NCT01158183 is a clinical study titled "Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis". A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.
What is the current status of trial NCT01158183?
This trial is currently completed. The enrollment target is 226 participants. The study started on 2007-07. Estimated completion is 2009-09.
What interventions are being tested in trial NCT01158183?
The interventions under investigation include: BAY86-5046_Interferon-beta-1b (DRUG).
Who is sponsoring clinical trial NCT01158183?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia